CClinicalTrials.gg
Status unknownNCT02822456Updated Dec 3, 2019

Intermittent Oro-Esophageal Tube Feeding Using Individually-Customized 3-Dimensional Printing

An interventional study of VFSS in Dysphagia, sponsored by Ulsan University Hospital. Status unknown at 1 site in Korea, Republic of. Per ClinicalTrials.gov, last updated 2019-12-03.

Sponsored by Ulsan University Hospital · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Dec 2019), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Sex
All
01

Study summary

The aim of this study is to test the clinical effectiveness of IOE tube using individually customized 3-dimentional printed guiding tube as an alternative to Levin tube feeding when unconscious patients have no choice but tube feeding.

Read the detailed description

According to standard Guideine of videofluoroscopic swallow study(VFSS), Patients referred to dysphagia(swallowing dysfunction)who were required to tube feeding and medically stable of vital sign, and agreed to participate. Participants with swallowing dysfunction who were classified into three groups (nasogastric tube, traditional intermittent (IOE) tube, individual 3D printed guiding tube) according to VFSS.

Both traditional IOE tube and individual 3D printed guiding tube groups will receive training about procedure prior to the first feeding. All participants will be evaluated with satisfaction for tube feeding (EORTC QLQ-H\&N35) in 3 days from the start day of the tube feeding. On the day of oral feeding, participants will be evaluated with the questionnaires and clinical examination. If the participant is discharged in a state maintain the tube feeding, investigated further length stay at leaving the hospital. On the 1 month, 3 month from tube feeding, the investigators will follow-up and measure the questionnaires and clinical examination.

02

Conditions studied

  • Dysphagia

Browse trials for

Keywords

  • dysphagia
  • intermittent tube
  • individual 3D printed guiding tube
03

In context

Deglutition Disorders

710 studies on the registry are indexed under Deglutition Disorders; 219 are open to participants now.

This study's planned enrollment of 24 is below the median of 60 across 471 interventional studies indexed under Deglutition Disorders.

Browse Deglutition Disorders studies →

Lead sponsor

Ulsan University Hospital is the lead sponsor of 26 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Dysphagia patients to check in VFSS (videofluoroscopic swallow study)
  • Patients participating in the study agreement
  • Oral feeding is not possible (Need tube feeding)

Exclusion criteria

Exclusion Criteria:

  • Patient to reject the participation
  • Crico-pharyngeal incoordination
  • Impaired esophageal peristalsis
  • Impaired GI tract
  • Observed esophageal reflux
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Individual 3D-printed guided tube

    IOE tube feeding using individual 3D-printed guided tube and nelaton tube whenever they eat

    Procedure: VFSS

  • Active comparator
    traditional IOE tube

    classic IOE tube feeding using nelaton tube only whenever they eat

    Procedure: VFSS

  • Active comparator
    nasogastric tube

    nasogastric tube feeding using levin tube always

    Procedure: VFSS

Interventions

  • ProcedureVFSS

    VFSS using assignment of tube type among the interventions such as individual 3D printed guiding tube, traditional IOE tube, levin tube

06

What researchers measure

Primary outcomes

  1. change of EORTC QLQ - H&N35 index

    Details (inconvenience, discomfort, altered body image, social activities, family life, pain, ease of learning to use) satisfaction evaluation (3, 9, 10)

    Time frame: 1 month after start of tube feeding

Secondary outcomes

  1. complications

    whether aspiration pneumonia on Chest Radiography or not, Measurement at leave hospital or start oral feeding can be another endpoint

    Time frame: after 1st session (3days) and after 1 month, and after 3 months

  2. change Mid-arm circumference

    Time frame: before VFSS and 1 month and 3 months after start of tube feeding

  3. change of Serum albumin

    Time frame: before VFSS and 1 month and 3 months after start of tube feeding

  4. change of MRS index

    Time frame: before VFSS and 1 month and 3 months after start of tube feeding

  5. change of success rate (rate of elimination)

    Time frame: after 1st session (3days), after 1 month, and after 3 months

  6. change of EORTC QLQ - H&N35 index

    Measurement at leave hospital or start oral feeding can be another endpoint, Details (inconvenience, discomfort, altered body image, social activities, family life, pain, ease of learning to use) satisfaction evaluation (3, 9, 10)

    Time frame: after 1st session (3days) and after 3 months

07

Study locations

1 of 1 sites recruiting
  • Ulsan University Hospital
    Ulsan, 682-714, Korea, Republic of
    • Chang Ho Hwang, M.D., Ph.D. · Contact · chhwang1220ciba@gmail.com · +82-52-250-7210
    • Chang Ho Hwang, M.D., Ph.D. · Principal investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 3, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02822456
Lead sponsor
Ulsan University Hospital
Responsible party
Chang Ho Hwang (Associate Professor, Ulsan University Hospital) — Principal investigator
First posted
Jul 4, 2016
Start date
Dec 2015
Primary completion
Dec 2020 (estimated)
Completion
Dec 2020 (estimated)
Last update
Dec 3, 2019

Study contacts

Chang Ho Hwang
Contact
chhwang1220ciba@gmail.com
+82-52-250-8898
Chang Ho Hwang, M.D., Ph.D.
study director · Ulsan University Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion